1,080 Shares in United Therapeutics Corporation $UTHR Purchased by PSP Research LLC

PSP Research LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,080 shares of the biotechnology company’s stock, valued at approximately $526,000.

A number of other institutional investors also recently made changes to their positions in the company. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics during the fourth quarter worth approximately $31,000. Institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 14,440 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $472.13, for a total transaction of $6,817,557.20. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 550,413 shares of company stock valued at $305,867,937. Company insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research analyst reports. Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. HC Wainwright boosted their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Finally, Royal Bank Of Canada cut their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Trading Down 0.0%

Shares of UTHR stock opened at $566.80 on Wednesday. The stock has a market cap of $24.06 billion, a P/E ratio of 20.92, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60. The stock has a 50 day simple moving average of $561.48 and a 200 day simple moving average of $509.54. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $6.63 earnings per share. Analysts forecast that United Therapeutics Corporation will post 27.07 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.